The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.